Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) FCF Margin (2017 - 2025)

Historic FCF Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 396.57%.

  • Sutro Biopharma's FCF Margin rose 3703700.0% to 396.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 239.62%, marking a year-over-year decrease of 1682700.0%. This contributed to the annual value of 313.71% for FY2024, which is 2383000.0% down from last year.
  • Per Sutro Biopharma's latest filing, its FCF Margin stood at 396.57% for Q3 2025, which was up 3703700.0% from 70.3% recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's FCF Margin peaked at 258.94% during Q3 2022, and registered a low of 1211.53% during Q1 2025.
  • Its 5-year average for FCF Margin is 311.32%, with a median of 315.01% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 6041700bps in 2022, then plummeted by -7104000bps in 2025.
  • Sutro Biopharma's FCF Margin (Quarter) stood at 226.37% in 2021, then crashed by -39bps to 315.47% in 2022, then soared by 104bps to 11.11% in 2023, then plummeted by -4526bps to 491.63% in 2024, then grew by 19bps to 396.57% in 2025.
  • Its FCF Margin stands at 396.57% for Q3 2025, versus 70.3% for Q2 2025 and 1211.53% for Q1 2025.